Frequently Asked Questions

Spike protein persistence refers to the continued detection of SARS-CoV-2 spike protein (or vaccine-encoded spike) in blood, fluids, or tissues after the acute phase of infection or vaccination. Durations reported in literature range from days to, in some studies, months or years depending on assay sensitivity, tissue type, and cohort.

Some cohort studies report correlation between circulating spike and multi-system symptoms resembling Long COVID, but population-level studies often show inconsistent associations. Causality has not been established in prospective trials. Spike may be one of several contributing factors alongside viral reservoirs, autoimmunity, and microvascular dysfunction.

Both can be detected post-exposure, but kinetics differ. Vaccine-derived spike/mRNA is typically cleared faster in most individuals, while subsets show prolonged detection. Infection may produce higher peak antigen loads. Assays often cannot distinguish source without sequencing.

Reports vary: many studies show clearance within weeks, while ultra-sensitive assays detect low pg/mL levels for months. The 2026 systematic review cites blood persistence up to ~709 days in some cohorts. These represent outliers, not population medians.

No FDA-approved therapy specifically targets vaccine-derived spike clearance. Investigational approaches include monoclonal antibodies (e.g., pemivibart), therapeutic apheresis (SPEAR trial), and in vitro enzyme studies (nattokinase). None are established standard of care.

Proposed mechanisms include endothelial damage, neuroinflammation, immune dysregulation, exosomal signaling, fibrin-resistant microclots (S1 subunit), and tissue antigen reservoirs in lymph nodes. Evidence levels vary from in vitro to clinical observational.

No. spikeprotein.site is an educational literature resource. Always consult qualified healthcare professionals for diagnosis and treatment decisions.